AU6909194A
(en)
|
1993-05-14 |
1994-12-12 |
Board Of Regents, The University Of Texas System |
Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
|
CN1052730C
(zh)
*
|
1993-12-23 |
2000-05-24 |
诺沃挪第克公司 |
具有生长激素释放特性的化合物
|
SK281963B6
(sk)
*
|
1993-12-23 |
2001-09-11 |
Novo Nordisk A/S |
Zlúčeniny ovplyvňujúce uvoľňovanie rastového hormónu, farmaceutické prostriedky s ich obsahom a ich použitie
|
US20020111461A1
(en)
*
|
1999-05-21 |
2002-08-15 |
Todd C. Somers |
Low molecular weight peptidomimetic growth hormone secretagogues
|
US5798337A
(en)
*
|
1994-11-16 |
1998-08-25 |
Genentech, Inc. |
Low molecular weight peptidomimetic growth hormone secretagogues
|
EP0833845A1
(de)
*
|
1995-06-22 |
1998-04-08 |
Novo Nordisk A/S |
Verbindungen mit wachstumshormon-freisetzenden eigenschaften
|
BR9708854A
(pt)
*
|
1996-04-24 |
1999-08-03 |
Novo Nordisk As |
Composto composição farmacêutica processo para estimular a liberação do hormônio do crescimento pela pituitária e para aumentar a taxa e grau de crescimento de animais e uso de um composto
|
AU7906998A
(en)
|
1997-06-20 |
1999-01-04 |
Novo Nordisk A/S |
Compounds with growth hormone releasing properties
|
US6127341A
(en)
*
|
1997-06-20 |
2000-10-03 |
Novo Nordisk A/S |
Compounds with growth hormone releasing properties
|
US6329342B1
(en)
|
1997-08-19 |
2001-12-11 |
Eli Lilly And Company |
Treatment of congestive heart failure with growth hormone secretagogues
|
ZA987383B
(en)
*
|
1997-08-19 |
2000-02-17 |
Lilly Co Eli |
Treatment of congestive heart failure with growth hormone secretagogues.
|
WO1999036431A1
(en)
|
1998-01-16 |
1999-07-22 |
Novo Nordisk A/S |
Compounds with growth hormone releasing properties
|
WO1999039730A1
(fr)
*
|
1998-02-09 |
1999-08-12 |
Kaken Pharmaceutical Co., Ltd. |
Preparation a administration orale contenant des peptides favorisant la secretion d'hormone de croissance
|
US6919315B1
(en)
|
1998-06-30 |
2005-07-19 |
Novo Nordisk A/S |
Compounds with growth hormone releasing properties
|
US6682908B1
(en)
|
1998-07-10 |
2004-01-27 |
Merck & Co., Inc. |
Mouse growth hormone secretagogue receptor
|
WO2000002919A1
(en)
|
1998-07-13 |
2000-01-20 |
Merck & Co., Inc. |
Growth hormone secretagogue related receptors and nucleic acids
|
WO2000009538A2
(en)
|
1998-08-10 |
2000-02-24 |
Merck & Co., Inc. |
Canine growth hormone secretagogue receptor
|
JP2002525265A
(ja)
*
|
1998-08-14 |
2002-08-13 |
アドミニストレイターズ オブ ザ トゥレーン エジュケーショナル ファウンド |
成長ホルモン放出活性を有する化合物
|
US6639076B1
(en)
|
1998-08-18 |
2003-10-28 |
Eli Lilly And Company |
Growth hormone secretagogues
|
US6696063B1
(en)
|
1998-12-30 |
2004-02-24 |
Applied Research Systems Ars Holding N.V. |
Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
|
KR100699404B1
(ko)
*
|
1999-02-18 |
2007-03-23 |
가켄 세야쿠 가부시키가이샤 |
성장 호르몬 분비촉진제로서의 신규 아미드 유도체
|
US7022677B1
(en)
|
1999-02-18 |
2006-04-04 |
Kaken Pharmaceutical Co., Ltd. |
Amide derivatives as growth hormone secretagogues
|
US6828331B1
(en)
|
1999-02-19 |
2004-12-07 |
Eli Lilly And Company |
Growth hormone secretagogues
|
ATE309358T1
(de)
*
|
1999-07-26 |
2005-11-15 |
Baylor College Medicine |
Superaktive, wachstumshormone freisetzende hormonanaloge vom schwein
|
US20040192593A1
(en)
|
1999-07-26 |
2004-09-30 |
Baylor College Of Medicine |
Protease resistant ti-growth hormone releasing hormone
|
US7022311B1
(en)
*
|
1999-10-12 |
2006-04-04 |
Kaken Pharmaceutical Co., Ltd. |
Powdery inhalational preparations and process for producing the same
|
UA73530C2
(uk)
|
1999-11-10 |
2005-08-15 |
Ново Нордіск А/С |
Сполука з властивостями вивільнювати гормон росту
|
JP3498041B2
(ja)
*
|
2000-05-29 |
2004-02-16 |
科研製薬株式会社 |
プラルモレリン含有点鼻用製剤
|
EP1159964B1
(de)
|
2000-05-31 |
2009-10-28 |
Pfizer Products Inc. |
Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
|
US7855229B2
(en)
|
2000-08-24 |
2010-12-21 |
University Of Tennessee Research Foundation |
Treating wasting disorders with selective androgen receptor modulators
|
US7919647B2
(en)
|
2000-08-24 |
2011-04-05 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US7645898B2
(en)
|
2000-08-24 |
2010-01-12 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and method of use thereof
|
US7622503B2
(en)
|
2000-08-24 |
2009-11-24 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
JP2004520395A
(ja)
|
2001-02-02 |
2004-07-08 |
コンジュケム,インコーポレーテッド |
長期持続性成長ホルモン放出因子誘導体
|
US7125840B2
(en)
*
|
2001-10-09 |
2006-10-24 |
Eli Lilly And Company |
Substituted dipeptides as growth hormone secretagogues
|
BR0213965A
(pt)
*
|
2001-10-26 |
2005-03-15 |
Baylor College Medicine |
Composição e método para alterar as propriedades de massa corporal magra e ósseas em um indivìduo
|
US20070066568A1
(en)
|
2005-08-31 |
2007-03-22 |
Dalton James T |
Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
|
US8853266B2
(en)
|
2001-12-06 |
2014-10-07 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators for treating diabetes
|
US6831102B2
(en)
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
EP1465654B1
(de)
|
2001-12-11 |
2015-02-25 |
Inovio Pharmaceuticals, Inc. |
Durch plasmid übertragene supplementierung zur behandlung chronisch kranker patienten
|
US7015219B2
(en)
|
2001-12-19 |
2006-03-21 |
Bristol-Myers Squibb Company |
3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators
|
AU2003215082B2
(en)
*
|
2002-02-07 |
2011-11-10 |
Baylor College Of Medicine |
Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
|
US7772433B2
(en)
|
2002-02-28 |
2010-08-10 |
University Of Tennessee Research Foundation |
SARMS and method of use thereof
|
US7381730B2
(en)
|
2002-03-15 |
2008-06-03 |
Bristol-Myers Squibb Company |
3-arylquinazoline derivatives as selective estrogen receptor beta modulators
|
US20060167268A1
(en)
*
|
2002-04-09 |
2006-07-27 |
Eli Lilly And Company, Patent Division, |
Growth hormone secretagogues
|
WO2003087069A2
(en)
*
|
2002-04-09 |
2003-10-23 |
Eli Lilly And Company |
Dipeptidic growth hormone secretagogues
|
AU2003225305A1
(en)
|
2002-05-08 |
2003-11-11 |
Bristol-Myers Squibb Company |
Pyridine-based thyroid receptor ligands
|
US7405234B2
(en)
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
EP1536817A1
(de)
|
2002-08-23 |
2005-06-08 |
Gestion Univalor Société en Commandite |
Wachstumshormon freisetzende peptide zur behandlung oder vobeugung von atherosklerose und hypercholesterolämie
|
AU2003302084A1
(en)
|
2002-11-15 |
2004-06-15 |
Bristol-Myers Squibb Company |
Open chain prolyl urea-related modulators of androgen receptor function
|
US8309603B2
(en)
|
2004-06-07 |
2012-11-13 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
TW200504021A
(en)
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
US7105537B2
(en)
|
2003-01-28 |
2006-09-12 |
Bristol-Myers Squibb Company |
2-substituted cyclic amines as calcium sensing receptor modulators
|
WO2004067719A2
(en)
*
|
2003-01-28 |
2004-08-12 |
Advisys, Inc. |
Growth hormone releasing hormone (ghrh) for use in reducing culling in herd animals
|
US7205322B2
(en)
|
2003-02-12 |
2007-04-17 |
Bristol-Myers Squibb Company |
Thiazolidine compounds as calcium sensing receptor modulators
|
US7557143B2
(en)
|
2003-04-18 |
2009-07-07 |
Bristol-Myers Squibb Company |
Thyroid receptor ligands
|
TW200424214A
(en)
*
|
2003-04-21 |
2004-11-16 |
Advisys Inc |
Plasmid mediated GHRH supplementation for renal failures
|
US7459460B2
(en)
|
2003-05-28 |
2008-12-02 |
Bristol-Myers Squibb Company |
Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
|
US7265145B2
(en)
|
2003-05-28 |
2007-09-04 |
Bristol-Myers Squibb Company |
Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
|
US7476653B2
(en)
|
2003-06-18 |
2009-01-13 |
Tranzyme Pharma, Inc. |
Macrocyclic modulators of the ghrelin receptor
|
EP1660530A2
(de)
*
|
2003-08-04 |
2006-05-31 |
Advisys, Inc. |
Für canine spezifisches wachstumshormon freisetzendes hormon
|
WO2005041998A1
(en)
|
2003-10-02 |
2005-05-12 |
Ali Sadat M |
Peptide for promoting healing of fractures
|
ATE467417T1
(de)
|
2003-12-31 |
2010-05-15 |
VGX Pharmaceuticals LLC |
Reduzierung von arthritis und lahmheit bei personen unter supllement von wachstumshormon freisetzendem hormon (ghrh)
|
DE602005027661D1
(de)
*
|
2004-01-20 |
2011-06-09 |
VGX Pharmaceuticals LLC |
Isetzendem hormon (ghrh) aus muskelzellen durch speziesspezifisches signalpeptid
|
US20050164952A1
(en)
*
|
2004-01-23 |
2005-07-28 |
Vital Pharmaceuticals, Inc. |
Delivery system for growth hormone releasing peptides
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7696241B2
(en)
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
US9889110B2
(en)
|
2004-06-07 |
2018-02-13 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator for treating hormone-related conditions
|
US9884038B2
(en)
|
2004-06-07 |
2018-02-06 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator and methods of use thereof
|
NZ553274A
(en)
*
|
2004-07-23 |
2010-02-26 |
VGX Pharmaceuticals LLC |
Growth hormone releasing hormone enhances the immune response induced by vaccination
|
EP2389941A1
(de)
|
2004-08-18 |
2011-11-30 |
Elixir Pharmaceuticals, Inc. |
Wachstumshormonsekretagoge
|
WO2006116401A1
(en)
|
2005-04-28 |
2006-11-02 |
Bristol-Myers Squibb Company |
C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
|
CU23558A1
(es)
|
2006-02-28 |
2010-07-20 |
Ct Ingenieria Genetica Biotech |
Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
|
US8058253B2
(en)
*
|
2006-07-06 |
2011-11-15 |
Vgx Pharmaceuticals, Inc. |
Growth hormone releasing hormone treatment to decrease cholesterol levels
|
EP2038252B1
(de)
|
2006-07-12 |
2016-11-02 |
University of Tennessee Research Foundation |
Substituierte acylanilide und verfahren zu ihrer verwendung
|
ES2558517T3
(es)
|
2006-08-02 |
2016-02-04 |
Cytokinetics, Inc. |
Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas
|
US8299248B2
(en)
|
2006-08-02 |
2012-10-30 |
Cytokinetics, Incorporated |
Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
|
US9730908B2
(en)
|
2006-08-24 |
2017-08-15 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
US9844528B2
(en)
|
2006-08-24 |
2017-12-19 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
US10010521B2
(en)
|
2006-08-24 |
2018-07-03 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
WO2008024456A2
(en)
|
2006-08-24 |
2008-02-28 |
University Of Tennessee Research Foundation |
Substituted acylanilides and methods of use thereof
|
EP2118080B1
(de)
|
2007-02-09 |
2016-08-31 |
Ocera Therapeutics, Inc. |
Makrocyclische ghrelin-rezeptormodulatoren und verwendungsverfahren dafür
|
WO2008134828A2
(en)
|
2007-05-04 |
2008-11-13 |
Katholieke Universiteit Leuven |
Tissue degeneration protection
|
US7968603B2
(en)
|
2007-09-11 |
2011-06-28 |
University Of Tennessee Research Foundation |
Solid forms of selective androgen receptor modulators
|
WO2009155481A1
(en)
|
2008-06-20 |
2009-12-23 |
Gtx, Inc. |
Metabolites of selective androgen receptor modulators and methods of use thereof
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
WO2011133920A1
(en)
|
2010-04-23 |
2011-10-27 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
WO2013190520A2
(en)
|
2012-06-22 |
2013-12-27 |
The General Hospital Corporation |
Gh-releasing agents in the treatment of vascular stenosis and associated conditions
|
US10314807B2
(en)
|
2012-07-13 |
2019-06-11 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US9622992B2
(en)
|
2012-07-13 |
2017-04-18 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
EP3733170A1
(de)
|
2012-07-13 |
2020-11-04 |
Oncternal Therapeutics, Inc. |
Verfahren zur behandlung von androgenrezeptor(ar)-positivem brustkrebs mit selektivem androgenrezeptormodulator (sarms)
|
US9744149B2
(en)
|
2012-07-13 |
2017-08-29 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
US9969683B2
(en)
|
2012-07-13 |
2018-05-15 |
Gtx, Inc. |
Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
|
US10258596B2
(en)
|
2012-07-13 |
2019-04-16 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US10987334B2
(en)
|
2012-07-13 |
2021-04-27 |
University Of Tennessee Research Foundation |
Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
|
WO2014065341A1
(ja)
|
2012-10-24 |
2014-05-01 |
第一三共株式会社 |
筋萎縮性側索硬化症治療剤
|
JP2016518357A
(ja)
|
2013-04-08 |
2016-06-23 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
骨格筋幹細胞を若返らせる方法および組成物
|
US9119832B2
(en)
|
2014-02-05 |
2015-09-01 |
The Regents Of The University Of California |
Methods of treating mild brain injury
|
US10328082B2
(en)
|
2014-05-30 |
2019-06-25 |
Pfizer Inc. |
Methods of use and combinations
|
WO2017075535A1
(en)
|
2015-10-28 |
2017-05-04 |
Oxeia Biopharmaceuticals, Inc. |
Methods of treating neurodegenerative conditions
|
MA56396A
(fr)
|
2019-06-27 |
2022-05-04 |
Cytokinetics Inc |
Polymorphes de 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)méthyl)amino)pyrimidin-5-yl)-1h-pyrrole-3-carboxamide
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|